BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: sitravatinib-matching placeboDrug: tislelizumab-matching placebo
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05564338
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 43
- Registration Number
- NCT05547399
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT05494762
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- LeukemiaLymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic LymphomaRelapsed Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT05479994
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Mantle Cell LymphomaRefractory Mantle Cell Lymphoma (MCL)Relapsed Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT05471843
- Locations
- 🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 96
- Registration Number
- NCT05461794
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05387668
- Locations
- 🇺🇸
PPD, Las Vegas, Nevada, United States
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 157
- Registration Number
- NCT05381909
- Locations
- 🇺🇸
Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Scri Florida Cancer Specialists North, Saint Petersburg, Florida, United States
🇺🇸Florida Cancer Specialist (Scri) Sarasota, Sarasota, Florida, United States
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
- Conditions
- High-risk Neuroblastoma
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 8
- Registration Number
- NCT05373901
- Locations
- 🇨🇳
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳The Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China